The good news is that acid reflux on GLP-1 therapy is manageable and almost never requires stopping the medication
At baseline, CV disease and risk factors were managed with lipid-lowering medications (89%), platelet-aggregation inhibitors including aspirin (77%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (79%), and beta blockers (64%)
More Recent Semaglutide Trials Recently, 2,000 people with a BMI over 30 who were not diagnosed with diabetes took part in a double-blind trial
Most patients see significant weight loss over several months, not weeks, and individual results vary
In a separate trial involving T2D patients, semaglutide treatment decreased the risk of CKD and cardiovascular death by 24%, delaying the progression of kidney dysfunction over four years